THE CONSORTIUM FOR THE ACCELERATION OF INNOVATION AND ITS TRANSFER IN THE LYMPHOMA FIELD

Advancing LYMPHOMA Diagnosis & Treatment TOGETHER

contact@calym.org | www.calym.org
CALYM, AN INSTITUTE
DEVOTED TO RESEARCH AND DEVELOPMENT
OF SOLUTIONS FOR THE TREATMENT
AND DIAGNOSIS OF LYMPHOMA

Accredited Carnot* institute in 2011, by the French Government, CALYM gathers 15 multidisciplinary and complementary preclinical and clinical research entities of scientists, teachers-researchers, physicians and clinical research professionals in the exclusive field of lymphoma:

• 2 non-profit research associations:
  - The Lymphoma Study Association (LYSA), cooperative group, international leader of lymphoma research
  - The Lymphoma Academic Research Organisation (LYSARC), largest European academic organization devoted to clinical research operations in the lymphoma field

• 13 academic research teams of excellence:
  based in universities and hospitals across France, conducting research activities on lymphoma

* Carnot institutes are public research organizations, accredited by the French Government, that are strongly committed to conduct and develop partnership research activity for the innovation of companies – from SMEs to big pharmaceutical companies – and socio-economic actors.

LYMPHOMA KEY FIGURES

1st
blood cancer

80
lymphoma subtypes classified by the World Health Organization

13/100,000 cases in France

1st
more than 70,000 new cases/year in Europe
80,000 in the USA, 12,000 in France

2 millions patients worldwide (estimation)

Incidence x2 since the 70’s

A COMPLEX DISEASE

THE MARKET

$6,500M in 2009 / about $12,000 in 2017
only for non-Hodgkin lymphomas (90% of lymphomas)

PATIENTS

Montpellier
UMR5235 Uzé

Lyon
LYSA
LYSARC
UMR1052 Salles
UMR1052 Dumontet

Villejuif
UMR1170 Bernard

Marseille
U1104 UMR7280 Nadel
U1068 UMR7258 Olive

Créteil
U955 Gaulard

Rouen
U1245 Jardin

Rennes
UMR1236 Tarte

Toulouse
UMR1037 Brousset

Limoges
UMR7276 Cogné/Feuillard

Nantes
U1232 Amiot

Paris
U1163 Hermine
Our approach of integrated research from the bench to the bedside of the patient and vice versa is a major asset to advance research against lymphoma, particularly in the translational phase.

CALYM is the response to the needs of life science companies. We offer our unique expertise, scientific skills, resources and means at all levels of our R&D approach.
DISCOVER OUR PARTNERSHIP OFFER
FROM THE IDENTIFICATION OF NEW BIOLOGICAL TARGETS TO INTERNATIONAL PHASE III CLINICAL TRIALS AND BEYOND

THE RECOGNIZED EXPERTISE of our teams in studying signaling pathways, the physiology of normal and pathological lymphoid tissue, the microenvironment and the mode of action of monoclonal antibodies, offer the opportunity to explore new therapeutic pathways for the development of more targeted, better tolerated and more effective drugs.

Our studies lead us to create and enrich unparalleled BIOLOGICAL COLLECTIONS in order to develop new innovative MODELS closer to the biology that represent an important collaborative potential to provide proof of concept, elucidate the mode of action of drug candidates and conduct suitable and effective preclinical studies.

We have been successfully collaborating for more than 30 years with pharmaceutical and biotechnology companies to design and conduct CLINICAL TRIALS in lymphoma, from Phase I (including first-in-man) to Phase III (including international registration trials) and beyond (Phase IV, registers).

In addition, CALYM conducts and supports more and more NON-INTERVENTIONAL AND ANCILLARY biological, histopathological, imaging, statistical and bioinformatics studies.

Our studies lead us to create and enrich unparalleled BIOLOGICAL COLLECTIONS in order to develop new innovative MODELS closer to the biology that represent an important collaborative potential to provide proof of concept, elucidate the mode of action of drug candidates and conduct suitable and effective preclinical studies.

We have been successfully collaborating for more than 30 years with pharmaceutical and biotechnology companies to design and conduct CLINICAL TRIALS in lymphoma, from Phase I (including first-in-man) to Phase III (including international registration trials) and beyond (Phase IV, registers).

In addition, CALYM conducts and supports more and more NON-INTERVENTIONAL AND ANCILLARY biological, histopathological, imaging, statistical and bioinformatics studies.

---

**CeVi collection (ISO 9001:2008):**
1,000+ samples of cryopreserved viable cells of lymphomas and reactive tissues and 4,000+ tubes

**TENOMIC collection:**
900+ clinically annotated samples of T-cell lymphoma patients

**Clinical-biological annotated database of 23,000+ lymphoma patients**

**Proprietary imaging database of 18,000+ medical examinations**

**In vitro, ex vivo and in vivo models** reflecting genetic disorders and microenvironment associated to each lymphoma subtype

---

**UNIQUE BIOLOGICAL COLLECTIONS, DATABASES & MODELS**
Humanized mouse MODELS, preclinical mouse models, transgenic, lymphomagenesis, xenograft, resistance mouse models (Rituximab, GA101, R-CHOP)

PRECLINICAL IMAGING PLATFORM: microscopy, multiphotonic, fluorescence, MET, MEB, confocal, NanoSIMS 50, small animal imaging...

MODELS OF CELL LINES, primary cells, screening

OMICS TECHNICAL PLATFORMS: genomics, transcriptomics, proteomics, metabolomics, lipidomics

FUNCTIONAL, standardized ex-vivo ASSAYS, multicenter clinical-grade immunophenotyping on fresh samples, single cell analysis

BIOLOGICAL COLLECTIONS of viable cryopreserved lymphoma cells and reactive tissues (CeVi collection), tumors (slides, paraffin embedded, frozen, Tissue Micro Array, DNA/RNA), blood (plasma, DNA/RNA)

CLINICAL GRADE PLATFORMS: flow cytometry, centralized review of imaging examinations (LYSA-M), centralized review of tissue samples (LYSA-P), telepathology platform, bioinformatics

TOXICOLOGY* EARLY PHASE CLINICAL RESEARCH PLATFORM OF LYSA-LYSARC: Phase I/IIa, first-in-man, first-in-lymphoma or first combo studies

Clinical, biological, pathological and imaging DATABASES (total database > 23,000 patients)

CLINICAL GRADE PLATFORMS

INTERRNTATIONAL PHASE III REGISTRATION TRIALS (new drug, new indication)

REGISTRIES, post-marketing safety surveillance, real life data studies, long term post-study follow-up
Ro-CHOP: A clinical trial in the long run
In partnership with a leading biopharmaceutical company in oncology-hematology, the addition of romidepsin to CHOP chemotherapy in first-line for peripheral T-cell lymphoma patients has been the subject of a complete clinical evaluation by LYSA-LYSARC, from Phase I to an international Phase III registration trial.

PRIMA: A Phase III clinical trial with many outputs
PRIMA Phase III clinical trial, conducted in 25 countries in collaboration with a big pharmaceutical group, led to the registration of rituximab as a two-year maintenance therapy for follicular lymphoma patients responding to first-line immunochemotherapy. PRIMA also generated many ancillary biological studies leading to a significant number of results and publications (including the Lancet) as well as a patent.

Examples of Collaborative Projects with Industry

A Quick and Easy Assay to improve diagnosis of large B-cell lymphoma
A patented assay (WO2015135935 A1) developed for the differentiation of large B-cell lymphoma sub-types (GCB vs ABC) using the RT-MLPA technology (multiplex ligation-dependent probe amplification) is available for licensing.

Diagnostic and therapeutic use of monoclonal antibodies for various lymphoma sub-types
Several antibodies playing a specific role in the lymphoma immune control by targeting molecules such as BTLA and ICOS were developed and patented by CALYM’s teams. They are available for licensing.

Various Terms of Collaborations

Covering all stages of your R&D in the lymphoma field
- Contract research partnerships on preclinical, translational or clinical projects
- Joint setting-up of projects on national or international calls for projects
- Access to our databases, technical platforms, biological collections, preclinical models, technical resources
- Expertise and consulting of internationally renowned lymphoma experts

Besides its platforms, CALYM offers a unique training, both scientific and operational, through The Lymphoma Academy, a LYSARC initiative to foster lymphoma R&D excellence.

Why Partner With Us?
Strong Commitments
- Single entry point to a network of scientific and technical skills and platforms
- Continuous improvement process
- Systematic answer in less than 5 days to partner requests (possible direction towards another structure of research)
- Full cost quotation
- Performing to deadlines
- Compliance with contractual commitments
- Follow-up of relationships with partners and assessment of their satisfaction

Quality Standards Insuring a Level of Optimal Performance
ISO 9001:2008 certifications for:
- The management and monitoring of CALYM’s partnership research activities
- The coordination of CALYM’s lymphoma viable cells CeVi collection

Accreditations by the French National Cancer Institute:
- LYSA-LYSARC “French Cooperative Intergroup of International Dimension in the Field of Cancer”
- 9 early phase centers (CLIP)

International quality standards: GCP, GLP, ICH

TAX BENEFITS
CALYM is accredited for the French research tax credit scheme (Crédit Impôt Recherche). Eligible entities (must be subject to corporate tax in France) having research contracts with CALYM can save up to 50% of audited R&D expenses.

Examples of Collaborative Projects with Industry

Ro-CHOP: A clinical trial in the long run
In partnership with a leading biopharmaceutical company in oncology-hematology, the addition of romidepsin to CHOP chemotherapy in first-line for peripheral T-cell lymphoma patients has been the subject of a complete clinical evaluation by LYSA-LYSARC, from Phase I to an international Phase III registration trial.

PRIMA: A Phase III clinical trial with many outputs
PRIMA Phase III clinical trial, conducted in 25 countries in collaboration with a big pharmaceutical group, led to the registration of rituximab as a two-year maintenance therapy for follicular lymphoma patients responding to first-line immunochemotherapy. PRIMA also generated many ancillary biological studies leading to a significant number of results and publications (including the Lancet) as well as a patent.

A Quick and Easy Assay to improve diagnosis of large B-cell lymphoma
A patented assay (WO2015135935 A1) developed for the differentiation of large B-cell lymphoma sub-types (GCB vs ABC) using the RT-MLPA technology (multiplex ligation-dependent probe amplification) is available for licensing.

Diagnostic and therapeutic use of monoclonal antibodies for various lymphoma sub-types
Several antibodies playing a specific role in the lymphoma immune control by targeting molecules such as BTLA and ICOS were developed and patented by CALYM’s teams. They are available for licensing.
300 university and hospital researchers including 40 PhD students

500+ physicians: clinicians, biologists, pathologists, radiologists, statisticians…

170 qualified staff for clinical research operations

120 clinical centers

750+ patients enrolled per year in clinical cases

70+ contracts with the industry per year

150+ R&D projects

80+ patents

Consolidated annual budget: more than €20M

CALYM is a member of:

GLOBAL CARE Initiative
(Carnot institutes of human health)
www.globalcare-initiative.com

FINDMED
(“Health-Medicines” Carnot sector)
www.findmed.fr

Institut Carnot CALYM
Centre Hospitalier Lyon-Sud
Secteur Sainte Eugénie - Pavillon 6D
69495 Pierre-Benite - France

contact@calym.org
www.calym.org

Tel.: +33 (0)4 72 24 41 71
Fax: +33 (0)4 72 66 38 57